OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Sotagliflozin (Sota) inhibits sodium glucose cotransporter 2 (SGLT2; IC(50)=1.8 nM) and SGLT1 (IC(50)=36 nM). In humans, Sota improves glycemic control in part by increasing urinary glucose excretion via renal SGLT2 inhibition. Sota also lowers postprandial glucose (PPG), likely by inhibiting intest...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, David, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555054/
http://dx.doi.org/10.1210/js.2019-OR22-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555054/
http://dx.doi.org/10.1210/js.2019-OR22-5

Ejemplares similares